
	Where results make sense

Topic: Ranbaxy Laboratories Limited

Related Topics

Engineers India Limited

Lists of companies

Raymond Textiles

Dabur India Limited

Videocon Electronics

National Thermal Power Corporation

Indian Oil Corporation

Hindustan Lever Limited

ONGC

HDFC

Godrej

Birla Corporation Limited

List of Indian companies

Larsen and Toubro

BPL (Indian electronics company)

	Ranbaxy Laboratories Ltd.
		RLL is truly a global company with presence in 40 countries and manufacturing facilities in 6 countries.
		RLL is growing at a fast pace in the export markets and is likely to achieve many more milestones in the years to come.
		RLL has presence in niche therapeutic segments and is the unbeatable leader in the antibiotics segment.
	www.valuenotes.com /krc/jul2301.asp?ArtCd=27576 (2323 words)

	Ranbaxy Laboratories Limited
		RLL has entered into co-marketing arrangement with Cipla, Glaxo SmithKline and Cadila Healthcare for these products.
		RLL has reported 9% growth in sales during the 3Q01 in the domestic market as compared to 7.5% market growth.
		RLL’s future valuations will be driven by its research success and continued success in exports.
	www.valuenotes.com /krc/oct1601.asp?ArtCd=27919 (1079 words)

	Press release : RANBAXY CompanynewsGroup
		As is customary, RLL will generate and provide appropriate scientific data supporting the efficacy of Zidovudine tablets in order to allow the U.S. FDA to technically review the formulation and grant final approval.
		RLL is committed to supporting PEPFAR by providing anti-retroviral agents that successfully pass regulatory scrutiny, and remain committed and dedicated as well, to supporting the needs of AIDS patients who are candidates for ARV pharmacotherapy.
		RLL's plan is to provide single entity products and fixed dose combination products in the future for FDA approval that can then be employed by PEPFAR to meet the clinical needs of patients.
	www.companynewsgroup.com /communique.asp?co_id=94017 (437 words)

	Ranbaxy Pharmaceuticals Inc. - Newsroom
		Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration, Office of Generic Drugs, to manufacture and market Gabapentin Tablets, 600 and 800 mg strengths.
		Ranbaxy Pharmaceuticals Inc. ("RPI") based in Jacksonville, Florida, is the wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company.
		Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients.
	www.ranbaxyusa.com /newsroom/04-12-10.htm (361 words)

	Ranbaxy and MMV achieve potential breakthrough in malaria drug
		Ranbaxy Laboratories Limited (Ranbaxy) and Medicines for Malaria Venture (MMV) announced today that a potential breakthrough antimalarial drug has entered into human clinical trials.
		Ranbaxy Laboratories Ltd, MMV’s pharmaceutical partner for the development of this drug, has obtained authorisation from Medicines and Healthcare Products Regulatory Agency (MHPRA) to conduct clinical trials in the United Kingdom.
		Ranbaxy is committed to developing a drug that is not only safe and effective, but also affordable to people in India and hundreds of millions others who have to live with this terrible disease everyday.”
	www.medicalnewstoday.com /medicalnews.php?newsid=12352 (977 words)

	Ranbaxy Pharmaceuticals Inc. - Corporate Information
		Ranbaxy Pharmaceuticals Inc. (RPI), and Ranbaxy Laboratories Inc. (RLI), were created to achieve the vision and mission of Ranbaxy Laboratories Limited, its parent company, to become a research based international pharmaceutical company.
		RLI, also a wholly owned subsidiary of Ranbaxy Laboratories Limited, is the branded prescription division in the US market and will expand and grow through our R&D efforts, continued exploration of novel drug delivery systems, licensing activities, mergers and acquisitions.
		Ranbaxy Laboratories Limited is positioned today as the tenth largest* generic pharmaceutical company in the world.
	www.ranbaxyusa.com /corporate/index.htm (241 words)

	Ranbaxy Laboratories - Company Profile - Pharmaceutical Business Review
		Ranbaxy Laboratories is headquartered in New Delhi, India.
		Ranbaxy's product portfolio has been carefully reviewed with regard to the new product patent regime in India and we have concluded that our portfolio will not be affected by the changed patent environment to any significant extent.
		It has been highlighted that all members of the Ranbaxy staff are expected to not only act with a high degree of professionalism, earnestness and diligence in their assigned duties, but also to uphold the highest standards of ethical integrity at all times.
	www.pharmaceutical-business-review.com /companyprofile.asp?guid=07C112BA-D49F-4A9E-9EB4-1630A9D4F8E6 (1878 words)

	Ranbaxy Pharmaceuticals Inc. - Newsroom
		Ranbaxy's strengths and vibrancy in research and development, product development and world class manufacturing, lends to its recognition as one of the world's leading suppliers of generic pharmaceuticals.
		Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary, was created to meet the changing needs of the global pharmaceutical industry and its customers.
		Ranbaxy was granted approval for its first product, Cefaclor, by the FDA in 1997, and initiated marketing in January of 1998.
	www.ranbaxyusa.com /newsroom/98_04_09.htm (319 words)

	Ranbaxy Laboratories Limited (Site not responding. Last check: 2007-11-04)
		Ranbaxy Laboratories Limited (RLL), announced today that the Company has received tentative approval from the US Food and Drug Administration to manufacture...
		Bhd (RMSB), a subsidiary of Ranbaxy Laboratories Limited, today announced the commissioning of its new manufacturing facility in Sungai Petani near Kedah in...
		NEW DELHI: Ranbaxy Laboratories Limited on Wednesday said that it has received USFDA tentative approval for Sumatriptan Succinate Tablets.
	www.wikiverse.org /ranbaxy-laboratories-limited (171 words)

	Ranbaxy signs pact with Medicines for Malaria Venture for developing anti-malarial drug
		Ranbaxy Laboratories Limited today entered into an agreement with Medicines for Malaria Venture (MMV), Geneva, for the development of synthetic Peroxide anti-malarial drug, the company said in a release.
		Ranbaxy's team of scientists will work in collaboration with scientists and researchers from the University of Nebraska Medical Centre, Monash University and the Swiss Tropical Institute in identifying a candidate for development.
		Ranbaxy's R&D strengths in process chemistry, formulation development and other pre-clinical expertise, strong regulatory submission capabilities and cost effectiveness were the key considerations for MMV to partner with the company.
	www.expresspharmapulse.com /print.php?article=87 (636 words)

	Ranbaxy Charts Expansion Route (Site not responding. Last check: 2007-11-04)
		Ranbaxy Laboratories Limited, the domestic pharmaceutical major, is charting business expansion plans that traverse three continents.
		Ranbaxy acquired French generic firm RPG Aventis, for which it had signed the agreement two years back.
		Ranbaxy is also gung-ho about it growth prospects in the BRIC (Brazil, Rassia, India and China) market.
	www.indiapackagingshow.com /news/newsfiles/53.htm (240 words)

	Laboratories
		Moss Landing Marine Laboratories The Moss Landing Marine Laboratories is a multi-campus research facility of the Montere...
		Ranbaxy Laboratories Limited Ranbaxy Laboratories Limited is an USA, world's largest pharmaceuticals market.
		Survival Research Laboratories Survival Research Laboratories is a 2004, SRL has conducted 45 shows throughout the world...
	www.brainyencyclopedia.com /topics/laboratories.html (197 words)

	[No title] (Site not responding. Last check: 2007-11-04)
		The Board of Directors of Ranbaxy Laboratories Limited at their meeting held today took on record the unaudited results for the quarter ended September 30, 2003.
		The Net Consolidated Sales of Ranbaxy Laboratories Limited and its subsidiaries was at Rs.11,270 Mn (USD 245 Mn), registering a growth of 11% (2002 : Rs.10,134 Mn, USD 209 Mn).
		Ranbaxy has also submitted the clinical trials application for the molecule in South Africa, UK and Germany.
	www.ranbaxy.com.ua /news9.htm (1084 words)

	Ranbaxy Laboratories Limited - Wikipedia, the free encyclopedia
		Ranbaxy Laboratories Limited is an Indian company incorporated in 1961.
		It exports its products to over 70 countries with ground operations in 25 and manufacturing facilities in 7 countries.
		In 1998, Ranbaxy entered USA, world's largest pharmaceuticals market.
	en.wikipedia.org /wiki/Ranbaxy_Laboratories_Limited (85 words)

	Cumberland Pharmaceuticals - Press Release: March 31, 2003 (Site not responding. Last check: 2007-11-04)
		Proctosol-HC® is a topical, synthetic steroid, hydrocortisone cream distributed by Ranbaxy in the United States in both 1% and 2.5% strengths.
		Ranbaxy Laboratories Limited (RLL) is India's leading pharmaceutical company and develops, manufactures and markets generic and proprietary prescription pharmaceutical products.
		Ranbaxy Pharmaceuticals Inc. is a wholly-owned subsidiary of RLL and is now the largest contributor to RLL's sales.
	www.cumberlandpharma.com /pr030331.htm (384 words)

	www.presstrust.com - Ranbaxy's all Round Performance Boosts Q1 Global Sales by 18% (Site not responding. Last check: 2007-11-04)
		The Board of Directors of Ranbaxy Laboratories Limited at their meeting held today, approved the audited accounts for the year ended December 31, 2003 and the unaudited results for the quarter ended March 31, 2004.
		Ranbaxy's operations in USA clocked sales of USD 104.5 Mn, despite the genericisation of one of its key product.i.e.
		Ranbaxy launched its urology brand, Forzest (Tadalafil), which is the most recently approved prescription medicine for the treatment of Erectile Dysfunction (ED) in men.
	www.presstrust.com /article2034.html (1122 words)

	Ranbaxy Labs announces launch of its generic Cialis brand, Forzest (Tadalafil).
		Ranbaxy Labs announces launch of its generic Cialis brand, Forzest (Tadalafil).
		Ranbaxy Laboratories Limited announced the launch of its brand, Forzest (Tadalafil) in India.
		Ranbaxy Laboratories Limited, India's largest Rx pharmaceutical company, manufactures and markets branded generic drugs and Active Pharmaceutical Ingredients.
	www.mens-sexual-health.org /forzestnews.html (510 words)

	[No title] (Site not responding. Last check: 2007-11-04)
		Six of Ranbaxy's anti-AIDS products (10 Dosage Forms/approvals in all) have been pre-qualified by the WHO, of which 4 are Anti-Retrovirals (ARVs) -- the largest offering of any generics company.
		Ranbaxy offers one of the largest ranges of bio-equivalent generic ARVs, viz.
		Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.
	www.panapress.com /newswire.asp?code=904 (430 words)

	NSE - Press Releases - April 20, 2001 (Site not responding. Last check: 2007-11-04)
		The National Stock Exchange of India Limited has declared the trading member Shalibhadra Securities Ltd. a defaulter, with effect from April 20, 2001, due to the failure of the trading member in meeting their obligations/liabilities to the Exchange/Clearing Corporation.
		The press today had reports that Ranbaxy is believed to have internally estimated the maximum loss that it may have to incur through its wholly owned finance subsidiary Vidyut Investment as a result of stock market crash, would be Rs.
		Ranbaxy Laboratories Limited has vide their letter dated April 20, 2001 stated "Vidyut Investment Limited (Vidyut) is a wholly owned subsidiary company of Ranbaxy Laboratories Limited (Ranbaxy).
	www.nseindia.com /content/press/20042001.htm (350 words)

	smartbahu.com - Ranbaxy HIV Update- January 2005 (Site not responding. Last check: 2007-11-04)
		Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company has so far made three filings of its Anti-Retrovirals (ARVs), to the USFDA for its approval under the expedited review process of the US Presidents Emergency Plan for AIDS Relief (PEPFAR).
		Ranbaxy is committed to making affordable, bio-equivalent ARVs accessible to HIV/AIDS patients throughout the world, particularly to those, who might not otherwise be able to access therapy.
		Ranbaxy's facilities in India at Paonta Sahib (Himachal Pradesh) that will manufacture these ARVs were inspected recently by the USFDA authorities and found to be compliant.
	www.smartbahu.com /article43273.html (407 words)

	ranbaxy (Site not responding. Last check: 2007-11-04)
		The Board of Directors of Ranbaxy Laboratories Limited at their meeting held today, took on record the unaudited results for the quarter ended September 30, 2002.
		The consolidated sales of Ranbaxy Laboratories Limited and its subsidiaries for the quarter ended September 30, 2002 (Q3) was Rs.
		In the area of biotechnology, Ranbaxy had identified vaccines as a key sub-segment for launch in India.
	www.ranbaxy.com /pressrelease_det.asp?sno=90 (1145 words)

	Ranbaxy may divest stake in Eli Lilly JV
		New Delhi, Dec 28: Ranbaxy Laboratories is planning to divest its stake in the 50:50 joint venture with Eli Lilly in India.
		Eli Lilly Ranbaxy, the joint venture between the US-based Eli Lilly and Ranbaxy Laboratories, recently introduced a new ergonomically-signed, reusable insulin delivery device - HumaPen, which provides insulin users with an easy and convenient way of injecting Lilly's Huminsulin (human insulin, recombinant DNA origin), including the fast-acting insulin analog, Humalog (insulin lispro, recombinant DNA origin).
		Ranbaxy entered into a global alliance agreement with Eli Lilly for marketing of pharmaceutical products in the US and other countries.
	www.financialexpress.com /fe/daily/20001229/fco29028.html (443 words)

	Ranbaxy HIV Update -- March 2005
		PRINCETON, N.J., March 23 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL) announced today that the Company has made two additional filings of its Anti-Retroviral (ARV) agents with the World Health Organization (WHO) for its approval, taking the total number of Ranbaxy ARV filings submitted with the WHO to five.
		At the same time, Ranbaxy has filed one more ARV with the U.S. FDA under its expedited review process for the President's Emergency Program for Aids Relief (PEPFAR), thus taking the total number of ARV filings with the FDA to four.
		Ranbaxy Inc., based in Princeton, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-23-2005/0003242949&EDATE= (289 words)

	Ranbaxy and Adcock Ingram Form Joint Venture in South Africa to Market Anti-Retroviral Products (Site not responding. Last check: 2007-11-04)
		Ranbaxy has been on the forefront in addressing the healthcare needs by providing cost-effective and quality medicines.
		Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development.
		The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 25 countries and manufacturing operations in 7 countries.
	www2.ccnmatthews.com /newsnet/2002/10/16/1016056n.html (456 words)

	BioSpace News for
		PRINCETON, N.J., August 2 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), 50 mg (base), and 100 mg (base).
		PRINCETON, N.J., July 21 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Glimepiride Tablets, 1 mg, 2 mg, 4 mg, and 8 mg.
		The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Glucophage(R) XR Extended-release Tablets, 750 mg.
	www.biospace.com /news_company.cfm?CompanyID=543719 (829 words)

	Ranbaxy and Adcock Ingram Form Joint Venture in South Africa to Market Anti-Retroviral Products
		NEW DELHI, India--(BUSINESS WIRE)--Oct. 16, 2002--Ranbaxy SA (Pty), a wholly owned subsidiary of Ranbaxy Laboratories Limited (Ranbaxy) and Tiger Brands' Healthcare division, Adcock Ingram, today announced the formation of a 50:50 joint venture to exclusively sell and distribute Ranbaxy's range of anti-retroviral products in South Africa.
		Commenting on the development, Dr Brian W. Tempest, President, Pharmaceuticals, Ranbaxy Laboratories Limited said, "This is a major step forward in deepening our business in South Africa and we are confident that the JV will realise a win-win situation for both the companies."
		Ranbaxy's continued focus on RandD has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.
	www.aegis.com /NEWS/BW/2002/BW021012.html (772 words)

	Ranbaxy granted marketing approval for metformin HCl extended release 500 mg tablets (Site not responding. Last check: 2007-11-04)
		Ranbaxy Laboratories Limited (RLL) announced that the company has received final approval from the US Food and Drug Administration to market Metformin hydrochloride extended-release tablets, 500 mg.
		The approval was granted after Barr Laboratories Inc, a wholly-owned subsidiary of Barr Pharmaceuticals, Inc (NYSE:BRL) selectively waived its rights to their exclusivity in favour of Ranbaxy.
		Ranbaxy Pharmaceuticals Inc based in Jacksonville, Florida, is the wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.
	www.expresspharmapulse.com /print.php?article=547 (280 words)

	Cumberland Pharmaceuticals - Press Release: June 15, 2004 (Site not responding. Last check: 2007-11-04)
		Under the terms of the alliance, Cumberland will collaborate with Ranbaxy on the sales, marketing, distribution and manufacturing of selected products while working to identify and evaluate future products with expected net sales of $30 to $50 million.
		Ranbaxy USA Inc. is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.
		RLL manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients.
	www.cumberlandpharma.com /pr040615.htm (320 words)

Try your search on: Qwika (all wikis)